FDA Approves Sotyktu (Deucravacitinib) for Psoriasis

This new psoriasis drug, a once-a-day pill, is a new option for people with moderate or severe symptoms who want to avoid injectable medications.

Related Keywords

New York ,United States ,Jessical Garelik ,Marisa Garshick ,Bristol Myers Squibb ,Langone Health ,Drug Administration ,New York City ,Improved Symptoms ,Over Half ,Psoriasis Area ,Severity Index ,Global Assessment ,